Viatris And Biocon’s US Bevacizumab Hit By Indefinite Delay

Potential Third Avastin Biosimilar Hit By COVID-19 Inspection Uncertainty

 
• By David Wallace
  
Blocks_Delay
Viatris’ bevacizumab application has been indefinitely delayed • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products